Evotec to Present at Two Upcoming IR Conferences

HAMBURG, Germany, Sept. 10, 2015 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT) (TecDAX, ISIN: DE0005664809) announced today that its CEO, Dr Werner Lanthaler, will present at the Morgan Stanley Global Healthcare Conference in New York, USA, and at the Berenberg & Goldman Sachs Fourth Annual German Corporate Conference, Munich, Germany.

Morgan Stanley Global Healthcare Conference at the Grand Hyatt in New York City
Date:Friday, 18 September 2015, 01.00 pm EDT
(07.00 pm CET)
Venue:Grand Hyatt, New York, NY, USA
Presenter:Dr Werner Lanthaler,
Chief Executive Officer of Evotec AG
Berenberg & Goldman Sachs Fourth Annual German Corporate Conference at the Dolce Hotel in Munich
Date:Tuesday, 22 September 2015, 01.45 pm CET
Venue:Dolce Hotel, Munich, Germany
Presenter:Dr Werner Lanthaler,
Chief Executive Officer of Evotec AG

About Evotec AG

Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic. The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, pain, metabolic diseases as well as oncology, inflammation and infectious diseases. Evotec has long-term discovery alliances with partners including Bayer, Boehringer Ingelheim, CHDI, Genentech, Janssen Pharmaceuticals, MedImmune/AstraZeneca, Roche and UCB. In addition, the Company has existing development partnerships and product candidates both in clinical and pre-clinical development. These include partnerships with Boehringer Ingelheim and MedImmune in the field of diabetes, with Janssen Pharmaceuticals in the field of depression and with Roche in the field of Alzheimer’s disease. For additional information please go to www.evotec.com.

FORWARD LOOKING STATEMENTS Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.

Contact Evotec AG: Gabriele Hansen, VP Corporate Communications & Investor Relations Phone: +49.(0)40.56081-255 gabriele.hansen@evotec.com

Source:Evotec AG